Loading…
An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2
In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of...
Saved in:
Published in: | Future science OA 2021-09, Vol.7 (8), p.FSO739-FSO739 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683 |
---|---|
cites | cdi_FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683 |
container_end_page | FSO739 |
container_issue | 8 |
container_start_page | FSO739 |
container_title | Future science OA |
container_volume | 7 |
creator | Cerino, Pellegrino Coppola, Annachiara Pierri, Biancamaria Volzone, Palmiero Bruzzese, Dario Pierri, Andrea Ferro, Amedeo Schiavi, Daniela Coppola, Antonio Miniero, Stefano Atripaldi, Luigi Pirozzi, Caterina Rusciano, Pasquale Macri, Alessandra Boenzi, Rita Sale, Silvia Brambilla, Gianfranco Buonerba, Carlo |
description | In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.
The AZD1222 vaccine against SARS-CoV-2 is effective in preventing COVID-19, but has been associated with rare, yet severe coagulation disorders. In this retrospective study, we reviewed available data obtained in a cohort of 67 citizens vaccinated with AZD1222. Four of them were prescribed low-dose aspirin or low-molecular-weight heparin for prevention of thrombosis by their family physician. Adverse events and biological parameters are also reported. Additional studies in larger cohorts are needed to interpret our findings. |
doi_str_mv | 10.2144/fsoa-2021-0064 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2841ec7ebc7c4a74b8a344062f2442b3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2841ec7ebc7c4a74b8a344062f2442b3</doaj_id><sourcerecordid>2554349878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEolXplbOPXFL8HYcD0mr5aKVKSBQ4cLEmznjXVTYutrNS-fUkTYXogZNnbL_PjPRU1WtGLziT8q3PEWpOOasp1fJZdcqp0rXSXDz_pz6pznO-pZSyudPcvKxOhOQtNUaeVnYzkthlTEcoIY4wkFym_p5ET4C4uI-pLLULJfzGMZOEDsMxjDtS9kg2Pz8wzjk5gnNhRAI7CGMu5Gbz9abexh81f1W98DBkPH88z6rvnz5-217W118-X20317WTRpa6UQi6650WCLyTzkPrhXFtQ7VS0KKg0DjBeoXMO98I2rTGdH3bGyWV0kacVVcrt49wa-9SOEC6txGCfbiIaWchleAGtNxIhq7BzjVOQiM7A0JKqrnnUvJOzKz3K-tu6g7YOxxLguEJ9OnLGPZ2F4_WcKa1bGfAm0dAir8mzMUeQnY4DDBinLLlSkkhW9Mse1-sX12KOSf0f8cwahfJdpFsF8l2kTwH3q0BP5UpYXYBR4d27eadwiLif-E_W26sPg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554349878</pqid></control><display><type>article</type><title>An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2</title><source>PubMed (Medline)</source><creator>Cerino, Pellegrino ; Coppola, Annachiara ; Pierri, Biancamaria ; Volzone, Palmiero ; Bruzzese, Dario ; Pierri, Andrea ; Ferro, Amedeo ; Schiavi, Daniela ; Coppola, Antonio ; Miniero, Stefano ; Atripaldi, Luigi ; Pirozzi, Caterina ; Rusciano, Pasquale ; Macri, Alessandra ; Boenzi, Rita ; Sale, Silvia ; Brambilla, Gianfranco ; Buonerba, Carlo</creator><creatorcontrib>Cerino, Pellegrino ; Coppola, Annachiara ; Pierri, Biancamaria ; Volzone, Palmiero ; Bruzzese, Dario ; Pierri, Andrea ; Ferro, Amedeo ; Schiavi, Daniela ; Coppola, Antonio ; Miniero, Stefano ; Atripaldi, Luigi ; Pirozzi, Caterina ; Rusciano, Pasquale ; Macri, Alessandra ; Boenzi, Rita ; Sale, Silvia ; Brambilla, Gianfranco ; Buonerba, Carlo</creatorcontrib><description>In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.
The AZD1222 vaccine against SARS-CoV-2 is effective in preventing COVID-19, but has been associated with rare, yet severe coagulation disorders. In this retrospective study, we reviewed available data obtained in a cohort of 67 citizens vaccinated with AZD1222. Four of them were prescribed low-dose aspirin or low-molecular-weight heparin for prevention of thrombosis by their family physician. Adverse events and biological parameters are also reported. Additional studies in larger cohorts are needed to interpret our findings.</description><identifier>ISSN: 2056-5623</identifier><identifier>EISSN: 2056-5623</identifier><identifier>DOI: 10.2144/fsoa-2021-0064</identifier><identifier>PMID: 34290884</identifier><language>eng</language><publisher>London, UK: Future Science Ltd</publisher><subject>adverse events ; AZD1222 ; coagulation ; COVID-19 ; SARS-CoV-2 ; Short Communication</subject><ispartof>Future science OA, 2021-09, Vol.7 (8), p.FSO739-FSO739</ispartof><rights>2021 The Authors</rights><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683</citedby><cites>FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216649/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216649/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Cerino, Pellegrino</creatorcontrib><creatorcontrib>Coppola, Annachiara</creatorcontrib><creatorcontrib>Pierri, Biancamaria</creatorcontrib><creatorcontrib>Volzone, Palmiero</creatorcontrib><creatorcontrib>Bruzzese, Dario</creatorcontrib><creatorcontrib>Pierri, Andrea</creatorcontrib><creatorcontrib>Ferro, Amedeo</creatorcontrib><creatorcontrib>Schiavi, Daniela</creatorcontrib><creatorcontrib>Coppola, Antonio</creatorcontrib><creatorcontrib>Miniero, Stefano</creatorcontrib><creatorcontrib>Atripaldi, Luigi</creatorcontrib><creatorcontrib>Pirozzi, Caterina</creatorcontrib><creatorcontrib>Rusciano, Pasquale</creatorcontrib><creatorcontrib>Macri, Alessandra</creatorcontrib><creatorcontrib>Boenzi, Rita</creatorcontrib><creatorcontrib>Sale, Silvia</creatorcontrib><creatorcontrib>Brambilla, Gianfranco</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><title>An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2</title><title>Future science OA</title><description>In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.
The AZD1222 vaccine against SARS-CoV-2 is effective in preventing COVID-19, but has been associated with rare, yet severe coagulation disorders. In this retrospective study, we reviewed available data obtained in a cohort of 67 citizens vaccinated with AZD1222. Four of them were prescribed low-dose aspirin or low-molecular-weight heparin for prevention of thrombosis by their family physician. Adverse events and biological parameters are also reported. Additional studies in larger cohorts are needed to interpret our findings.</description><subject>adverse events</subject><subject>AZD1222</subject><subject>coagulation</subject><subject>COVID-19</subject><subject>SARS-CoV-2</subject><subject>Short Communication</subject><issn>2056-5623</issn><issn>2056-5623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kU1v1DAQhiMEolXplbOPXFL8HYcD0mr5aKVKSBQ4cLEmznjXVTYutrNS-fUkTYXogZNnbL_PjPRU1WtGLziT8q3PEWpOOasp1fJZdcqp0rXSXDz_pz6pznO-pZSyudPcvKxOhOQtNUaeVnYzkthlTEcoIY4wkFym_p5ET4C4uI-pLLULJfzGMZOEDsMxjDtS9kg2Pz8wzjk5gnNhRAI7CGMu5Gbz9abexh81f1W98DBkPH88z6rvnz5-217W118-X20317WTRpa6UQi6650WCLyTzkPrhXFtQ7VS0KKg0DjBeoXMO98I2rTGdH3bGyWV0kacVVcrt49wa-9SOEC6txGCfbiIaWchleAGtNxIhq7BzjVOQiM7A0JKqrnnUvJOzKz3K-tu6g7YOxxLguEJ9OnLGPZ2F4_WcKa1bGfAm0dAir8mzMUeQnY4DDBinLLlSkkhW9Mse1-sX12KOSf0f8cwahfJdpFsF8l2kTwH3q0BP5UpYXYBR4d27eadwiLif-E_W26sPg</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Cerino, Pellegrino</creator><creator>Coppola, Annachiara</creator><creator>Pierri, Biancamaria</creator><creator>Volzone, Palmiero</creator><creator>Bruzzese, Dario</creator><creator>Pierri, Andrea</creator><creator>Ferro, Amedeo</creator><creator>Schiavi, Daniela</creator><creator>Coppola, Antonio</creator><creator>Miniero, Stefano</creator><creator>Atripaldi, Luigi</creator><creator>Pirozzi, Caterina</creator><creator>Rusciano, Pasquale</creator><creator>Macri, Alessandra</creator><creator>Boenzi, Rita</creator><creator>Sale, Silvia</creator><creator>Brambilla, Gianfranco</creator><creator>Buonerba, Carlo</creator><general>Future Science Ltd</general><general>Taylor & Francis Group</general><scope>FUSOA</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210901</creationdate><title>An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2</title><author>Cerino, Pellegrino ; Coppola, Annachiara ; Pierri, Biancamaria ; Volzone, Palmiero ; Bruzzese, Dario ; Pierri, Andrea ; Ferro, Amedeo ; Schiavi, Daniela ; Coppola, Antonio ; Miniero, Stefano ; Atripaldi, Luigi ; Pirozzi, Caterina ; Rusciano, Pasquale ; Macri, Alessandra ; Boenzi, Rita ; Sale, Silvia ; Brambilla, Gianfranco ; Buonerba, Carlo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse events</topic><topic>AZD1222</topic><topic>coagulation</topic><topic>COVID-19</topic><topic>SARS-CoV-2</topic><topic>Short Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cerino, Pellegrino</creatorcontrib><creatorcontrib>Coppola, Annachiara</creatorcontrib><creatorcontrib>Pierri, Biancamaria</creatorcontrib><creatorcontrib>Volzone, Palmiero</creatorcontrib><creatorcontrib>Bruzzese, Dario</creatorcontrib><creatorcontrib>Pierri, Andrea</creatorcontrib><creatorcontrib>Ferro, Amedeo</creatorcontrib><creatorcontrib>Schiavi, Daniela</creatorcontrib><creatorcontrib>Coppola, Antonio</creatorcontrib><creatorcontrib>Miniero, Stefano</creatorcontrib><creatorcontrib>Atripaldi, Luigi</creatorcontrib><creatorcontrib>Pirozzi, Caterina</creatorcontrib><creatorcontrib>Rusciano, Pasquale</creatorcontrib><creatorcontrib>Macri, Alessandra</creatorcontrib><creatorcontrib>Boenzi, Rita</creatorcontrib><creatorcontrib>Sale, Silvia</creatorcontrib><creatorcontrib>Brambilla, Gianfranco</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><collection>Future Science (Open Access)</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Future science OA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cerino, Pellegrino</au><au>Coppola, Annachiara</au><au>Pierri, Biancamaria</au><au>Volzone, Palmiero</au><au>Bruzzese, Dario</au><au>Pierri, Andrea</au><au>Ferro, Amedeo</au><au>Schiavi, Daniela</au><au>Coppola, Antonio</au><au>Miniero, Stefano</au><au>Atripaldi, Luigi</au><au>Pirozzi, Caterina</au><au>Rusciano, Pasquale</au><au>Macri, Alessandra</au><au>Boenzi, Rita</au><au>Sale, Silvia</au><au>Brambilla, Gianfranco</au><au>Buonerba, Carlo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2</atitle><jtitle>Future science OA</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>7</volume><issue>8</issue><spage>FSO739</spage><epage>FSO739</epage><pages>FSO739-FSO739</pages><issn>2056-5623</issn><eissn>2056-5623</eissn><abstract>In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings.
The AZD1222 vaccine against SARS-CoV-2 is effective in preventing COVID-19, but has been associated with rare, yet severe coagulation disorders. In this retrospective study, we reviewed available data obtained in a cohort of 67 citizens vaccinated with AZD1222. Four of them were prescribed low-dose aspirin or low-molecular-weight heparin for prevention of thrombosis by their family physician. Adverse events and biological parameters are also reported. Additional studies in larger cohorts are needed to interpret our findings.</abstract><cop>London, UK</cop><pub>Future Science Ltd</pub><pmid>34290884</pmid><doi>10.2144/fsoa-2021-0064</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2056-5623 |
ispartof | Future science OA, 2021-09, Vol.7 (8), p.FSO739-FSO739 |
issn | 2056-5623 2056-5623 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_2841ec7ebc7c4a74b8a344062f2442b3 |
source | PubMed (Medline) |
subjects | adverse events AZD1222 coagulation COVID-19 SARS-CoV-2 Short Communication |
title | An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A10%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20observational%20study%20of%20a%20cohort%20of%20citizens%20receiving%20the%20AZD1222%20vaccine%20against%20SARS-CoV-2&rft.jtitle=Future%20science%20OA&rft.au=Cerino,%20Pellegrino&rft.date=2021-09-01&rft.volume=7&rft.issue=8&rft.spage=FSO739&rft.epage=FSO739&rft.pages=FSO739-FSO739&rft.issn=2056-5623&rft.eissn=2056-5623&rft_id=info:doi/10.2144/fsoa-2021-0064&rft_dat=%3Cproquest_doaj_%3E2554349878%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-75ea6bdc63ea2b4cfa9f38c970655a9e30a7c31d5e1fcf7307988bd9d85455683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2554349878&rft_id=info:pmid/34290884&rfr_iscdi=true |